GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Total Assets

CLCS (Cell Source) Total Assets : $0.27 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cell Source Total Assets?

Cell Source's Total Assets for the quarter that ended in Sep. 2024 was $0.27 Mil.

During the past 12 months, Cell Source's average Total Assets Growth Rate was -1.20% per year. During the past 3 years, the average Total Assets Growth Rate was -6.30% per year. During the past 5 years, the average Total Assets Growth Rate was 28.80% per year. During the past 10 years, the average Total Assets Growth Rate was 6.60% per year.

During the past 12 years, Cell Source's highest 3-Year average Total Assets Growth Rate was 67.50%. The lowest was -39.10%. And the median was 12.50%.

Total Assets is connected with ROA %. Cell Source's annualized ROA % for the quarter that ended in Sep. 2024 was -1,631.08%. Total Assets is also linked to Revenue through Asset Turnover. Cell Source's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Cell Source Total Assets Historical Data

The historical data trend for Cell Source's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Total Assets Chart

Cell Source Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.45 0.31 0.41 0.20

Cell Source Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.20 0.08 0.43 0.27

Cell Source Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cell Source's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=-15.612+15.807
=0.20

Cell Source's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=-18.941+19.205
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source  (OTCPK:CLCS) Total Assets Explanation

Total Assets is connected with ROA %.

Cell Source's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-5.668/( (0.43+0.265)/ 2 )
=-5.668/0.3475
=-1,631.08 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cell Source's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (0.43+0.265)/ 2 )
=0/0.3475
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cell Source Total Assets Related Terms

Thank you for viewing the detailed overview of Cell Source's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Source Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Total Assets
Comparable Companies
AURX MRKR PIRS AGE BIXT CLRB NTBL ACST CRBP AIM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
57 West 57th Street, Suite 400, New York, NY, USA, 10019
Website
https://www.cell-source.com
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Executives
George Verstraete director 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave director, 10 percent owner 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner 10 percent owner
Yoram Drucker director 31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown director 100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat director, officer: CEO and CFO C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty director C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman director, 10 percent owner C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433